Notably, MAP4K4 levels were 2.7 ± 0.4-fold higher in participants with NAS≥5 (defines definite NASH; n=24) compared with participants with NAS≤4 (defines simple steatosis or borderline NASH; n=38) (Fig. 1E). This evidence concerns the gene MAP4K4 and metabolic dysfunction-associated steatohepatitis.